Showing results (181-190 of 191) with videos related to
Sort By:
Pageof 20
Arteriosclerosis, Thrombosis, and Vascular Biology|April 25, 2024
Mild Hypoxia Accelerates Cerebral Cavernous Malformation Disease Through CX3CR1-CX3CL1 SignalingEduardo Frias-Anaya, Helios Gallego-Gutierrez, Brendan Gongol, et al.Nature|May 11, 2017
Endothelial TLR4 and the microbiome drive cerebral cavernous malformationsAlan T Tang, Jaesung P Choi, Jonathan J Kotzin, et al.Translational Stroke Research|June 17, 2022
Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation DiseaseSharbel G Romanos, Abhinav Srinath, Ying Li, et al.Communications Medicine|March 3, 2023
Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angiomaAbhinav Srinath, Bingqing Xie, Ying Li, et al.Nature|April 28, 2021
PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanismAileen A Ren, Daniel A Snellings, Yourong S Su, et al.Stroke|December 22, 2023
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial ModelingStephanie Hage, Serena Kinkade, Romuald Girard, et al.Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Cavernous Angioma Symptomatic Hemorrhage (CASH) Trial Readiness II: Imaging Biomarkers and Trial ModelingStephanie Hage, Serena Kinkade, Romuald Girard, et al.Science Immunology|April 23, 2021
Longitudinal transcriptomics define the stages of myeloid activation in the living human brain after intracerebral hemorrhageMichael H Askenase, Brittany A Goods, Hannah E Beatty, et al.Lancet (London, England)|January 14, 2017
Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trialDaniel F Hanley, Karen Lane, Nichol McBee, et al.Lancet (London, England)|February 12, 2019
Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trialDaniel F Hanley, Richard E Thompson, Michael Rosenblum, et al.Pageof 20